<br>        Inclusion Criteria:<br><br>          -  Advanced Stage IIIB or IV non-small-cell lung cancer (NSCLC)<br><br>          -  Eastern Oncology Cooperative Group (ECOG) Performance Status 0 or 1<br><br>          -  Prior therapy defined as 1 prior systemic therapy for advanced disease<br><br>          -  Documented disease progression during or following most first line therapy for<br>             advanced disease<br><br>          -  Adequate hematologic, hepatic, renal function<br><br>        Exclusion Criteria:<br><br>          -  Epidermal growth factor receptor (EGFR) mutations<br><br>          -  Anaplastic lymphoma kinase (ALK) translocations<br><br>          -  Predominantly squamous, adenosquamous or unclear histologic type<br><br>          -  Active or untreated central nervous system (CNS) metastases<br><br>          -  Active malignancies other than NSCLC within the last 5 years with the exception of<br>             adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or<br>             squamous cell carcinoma of the skin<br><br>          -  Serious cardiac illness or medical conditions<br><br>          -  Pregnant or lactating women<br><br>          -  Uncontrolled intercurrent illness<br>      ;<br>        Inclusion Criteria:<br><br>          -  Advanced Stage IIIB or IV non-small-cell lung cancer (NSCLC)<br><br>          -  Eastern Oncology Cooperative Group (ECOG) Performance Status 0 or 1<br><br>          -  Prior therapy defined as 1 prior systemic therapy for advanced disease<br><br>          -  Documented disease progression during or following most first line therapy for<br>             advanced disease<br><br>          -  Adequate hematologic, hepatic, renal function<br><br>        Exclusion Criteria:<br><br>          -  Epidermal growth factor receptor (EGFR) mutations<br><br>          -  Anaplastic lymphoma kinase (ALK) translocations<br><br>          -  Predominantly squamous, adenosquamous or unclear histologic type<br><br>          -  Active or untreated central nervous system (CNS) metastases<br><br>          -  Active malignancies other than NSCLC within the last 5 years with the exception of<br>             adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or<br>             squamous cell carcinoma of the skin<br><br>          -  Serious cardiac illness or medical conditions<br><br>          -  Pregnant or lactating women<br><br>          -  Uncontrolled intercurrent illness<br>      ;<br>        Inclusion Criteria:<br><br>          -  Advanced Stage IIIB or IV non-small-cell lung cancer (NSCLC)<br><br>          -  Eastern Oncology Cooperative Group (ECOG) Performance Status 0 or 1<br><br>          -  Prior therapy defined as 1 prior systemic therapy for advanced disease<br><br>          -  Documented disease progression during or following most first line therapy for<br>             advanced disease<br><br>          -  Adequate hematologic, hepatic, renal function<br><br>        Exclusion Criteria:<br><br>          -  Epidermal growth factor receptor (EGFR) mutations<br><br>          -  Anaplastic lymphoma kinase (ALK) translocations<br><br>          -  Predominantly squamous, adenosquamous or unclear histologic type<br><br>          -  Active or untreated central nervous system (CNS) metastases<br><br>          -  Active malignancies other than NSCLC within the last 5 years with the exception of<br>             adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or<br>             squamous cell carcinoma of the skin<br><br>          -  Serious cardiac illness or medical conditions<br><br>          -  Pregnant or lactating women<br><br>          -  Uncontrolled intercurrent illness<br>      ;<br>        Inclusion Criteria:<br><br>          -  Advanced Stage IIIB or IV non-small-cell lung cancer (NSCLC)<br><br>          -  Eastern Oncology Cooperative Group (ECOG) Performance Status 0 or 1<br><br>          -  Prior therapy defined as 1 prior systemic therapy for advanced disease<br><br>          -  Documented disease progression during or following most first line therapy for<br>             advanced disease<br><br>          -  Adequate hematologic, hepatic, renal function<br><br>        Exclusion Criteria:<br><br>          -  Epidermal growth factor receptor (EGFR) mutations<br><br>          -  Anaplastic lymphoma kinase (ALK) translocations<br><br>          -  Predominantly squamous, adenosquamous or unclear histologic type<br><br>          -  Active or untreated central nervous system (CNS) metastases<br><br>          -  Active malignancies other than NSCLC within the last 5 years with the exception of<br>             adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or<br>             squamous cell carcinoma of the skin<br><br>          -  Serious cardiac illness or medical conditions<br><br>          -  Pregnant or lactating women<br><br>          -  Uncontrolled intercurrent illness<br>